These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Hughes RA; Wijdicks EF; Barohn R; Benson E; Cornblath DR; Hahn AF; Meythaler JM; Miller RG; Sladky JT; Stevens JC; Neurology; 2003 Sep; 61(6):736-40. PubMed ID: 14504313 [TBL] [Abstract][Full Text] [Related]
47. The Guillain-Barré syndrome. Fujimura H Handb Clin Neurol; 2013; 115():383-402. PubMed ID: 23931791 [TBL] [Abstract][Full Text] [Related]
48. Guillain-Barré syndrome: epidemiology, pathophysiology and management. Kuwabara S Drugs; 2004; 64(6):597-610. PubMed ID: 15018590 [TBL] [Abstract][Full Text] [Related]
49. [Guillain-Barre syndrome and IVIg: does early initiation of treatment influence the mean hospital stay?]. Coll-Cantí J; Alvarez-Ramo R; Dorado L; Guerrero C; Serichol M; Dávalos A; Martínez EM Neurologia; 2009 May; 24(4):217-9. PubMed ID: 19603290 [TBL] [Abstract][Full Text] [Related]
51. Posterior reversible encephalopathy and Guillain-Barré syndrome in a single patient: coincidence or causative relation? Van Diest D; Van Goethem JW; Vercruyssen A; Jadoul C; Cras P Clin Neurol Neurosurg; 2007 Jan; 109(1):58-62. PubMed ID: 16487653 [TBL] [Abstract][Full Text] [Related]
52. Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barré syndrome: critical reassessment of effectiveness and cost-efficiency. Oczko-Walker M; Manousakis G; Wang S; Malter JS; Waclawik AJ J Clin Neuromuscul Dis; 2010 Dec; 12(2):55-61. PubMed ID: 21386771 [TBL] [Abstract][Full Text] [Related]
53. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. van Koningsveld R; Schmitz PI; Meché FG; Visser LH; Meulstee J; van Doorn PA; Lancet; 2004 Jan; 363(9404):192-6. PubMed ID: 14738791 [TBL] [Abstract][Full Text] [Related]
54. Daily plasma exchange in severe Guillain-Barré syndrome helps in early weaning from ventilator: A lesson from a case. Kaur A; Bajpayee A; Bajpai NK; Kothari N Asian J Transfus Sci; 2017; 11(2):206-208. PubMed ID: 28970694 [TBL] [Abstract][Full Text] [Related]
55. Clinical Characteristics of Intravenous Injection of Monosialotetrahexosyl Ganglioside Sodium-Related Guillain-Barre Syndrome. Shi M; Zhu J; Deng H Front Neurol; 2019; 10():225. PubMed ID: 30930839 [No Abstract] [Full Text] [Related]
57. Guillain-Barré syndrome occurring synchronously with systemic lupus erythematosus as initial manifestation treated successfully with low-dose cyclophosphamide. Ali N; Rampure R; Malik F; Jafri SI; Amberker D J Community Hosp Intern Med Perspect; 2016; 6(2):30689. PubMed ID: 27124163 [TBL] [Abstract][Full Text] [Related]
58. Is a second cycle of immunoglobulin justified in axonal forms of Guillain-Barré syndrome? Godoy DA; Rabinstein A Arq Neuropsiquiatr; 2015 Oct; 73(10):848-51. PubMed ID: 26465402 [TBL] [Abstract][Full Text] [Related]
59. Treatment dilemmas in Guillain-Barré syndrome. Verboon C; van Doorn PA; Jacobs BC J Neurol Neurosurg Psychiatry; 2017 Apr; 88(4):346-352. PubMed ID: 27837102 [TBL] [Abstract][Full Text] [Related]
60. The usefulness of chief complaints to predict severity, ventilator dependence, treatment option, and short-term outcome of patients with Guillain-Barré syndrome: a retrospective study. Wang Y; Shang P; Xin M; Bai J; Zhou C; Zhang HL BMC Neurol; 2017 Nov; 17(1):200. PubMed ID: 29157205 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]